Hämatologie, Onkologie und Palliativmedizin

Schaich M, Röllig C, Soucek S, Kramer M, Thiede C, Mohr B, Oelschlaegel U,
Schmitz N, Stuhlmann R, Wandt H, Schäfer-Eckart K, Aulitzky W, Kaufmann M,
Bodenstein H, Tischler J, Ho A, Krämer A, Bornhäuser M, Schetelig J, Ehninger G.
Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study. J Clin Oncol. 2011 Jul 1;29(19):2696-702. Epub 2011 May 23. PubMed PMID: 21606413.

Röllig C, Bornhäuser M, Thiede C, Taube F, Kramer M, Mohr B, Aulitzky W,
Bodenstein H, Tischler HJ, Stuhlmann R, Schuler U, Stölzel F, von Bonin M, Wandt H, Schäfer-Eckart K, Schaich M, Ehninger G. Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European. LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System. J Clin Oncol. 2011 Jul 10;29(20):2758-65. Epub 2011 May 31. PubMed PMID: 21632498.

Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J,
Aulitzky WE, van der Kuip H. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to Cisplatin. PLoS One. 2011 Apr 21;6(4):e19198. PubMed PMID: 21532991; PubMed Central PMCID: PMC3080918.
 
Stölzel F, Pfirrmann M, Aulitzky WE, Kaufmann M, Bodenstein H, Bornhäuser M, Röllig C, Kramer M, Mohr B, Oelschlägel U, Schmitz N, Soucek S, Thiede C,
Ehninger G, Schaich M; Study Alliance Leukemia. Risk stratification using a new prognostic score for patients with secondary acute myeloid leukemia: results of the prospective AML96 trial. Leukemia. 2011 Mar;25(3):420-8. Epub 2010 Dec 7. PubMed PMID: 21135859.
 
Winkler B, Grapow M, Seeberger M, Matt P, Aulitzky W, Eckstein F. Heart
Failure Resulting from Giant Left Atrial Synovial Sarcoma Metastasis. Thorac
Cardiovasc Surg. 2011 Mar 21. [Epub ahead of print] PubMed PMID: 21425056.

Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M,
Platzbecker U, Stuhlmann R, Schuler U, Soucek S, Kramer M, Mohr B, Oelschlaegel U, Stölzel F, von Bonin M, Wermke M, Wandt H, Ehninger G, Schaich M; Study Alliance Leukemia. A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. Blood. 2010 Aug 12;116(6):971-8. Epub 2010 May 4. PubMed PMID: 20442365.

Haubeiss S, Schmid JO, Mürdter TE, Sonnenberg M, Friedel G, van der Kuip H,
Aulitzky WE. Dasatinib reverses cancer-associated fibroblasts (CAFs) from primary lung carcinomas to a phenotype comparable to that of normal fibroblasts. Mol Cancer. 2010 Jun 27;9:168. PubMed PMID: 20579391; PubMed Central PMCID: PMC2907332.

Skorta I, Oren M, Markwardt C, Gutekunst M, Aulitzky WE, van der Kuip H.
Imatinib mesylate induces cisplatin hypersensitivity in Bcr-Abl+ cells by
differential modulation of p53 transcriptional and proapoptotic activity. Cancer Res. 2009 Dec 15;69(24):9337-45. Epub . PubMed PMID: 19934315.

Engert A, Diehl V, Franklin J, Lohri A, Dörken B, Ludwig WD, Koch P, Hänel M,
Pfreundschuh M, Wilhelm M, Trümper L, Aulitzky WE, Bentz M, Rummel M, Sezer O, Müller-Hermelink HK, Hasenclever D, Löffler M. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol. 2009 Sep 20;27(27):4548-54. Epub 2009 Aug 24. PubMed PMID: 19704068.
 
Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon
W, Mürdter TE, Aulitzky WE.  Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer. 2008 Dec 11;8:364.

Cramer K, Nieborowska-Skorska M, Koptyra M, Slupianek A, Penserga ET, Eaves
CJ, Aulitzky W, Skorski T.  BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 2008 Sep 1;68(17):6884-8.

Henkes M, van der Kuip H, Aulitzky WE. Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec,Gleevectrade mark). Ther Clin Risk Manag. 2008 Feb;4(1):163-87.

Fanta S, Sonnenberg M, Skorta I, Duyster J, Miething C, Aulitzky WE, van der Kuip H.  Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells. Oncogene. 2008 Jul 17;27(31):4380-4. Epub 2008 Mar 24.

Bornhak S, Heidemann E, Herschlein HJ, Simon W, Merkle E, Widmaier G, Ernst R, Greulich M, Bittner R, Kieninger G, Merkle P, Strosche H, Karg C, Wellhaeusser U, Aulitzky W, Schmidt B, Metzger H, Hahn M, Stauch A, Meisner C, Selbmann HK, Regelmann C, Brinkmann F.  Symptom-oriented follow-up of early breast cancer is not inferior to conventional control. Results of a prospective multicentre study. Onkologie. 2007 Sep;30(8-9):443-9. Epub 2007 Sep 7.

Olofsson MH, Ueno T, Pan Y, Xu R, Cai F, van der Kuip H, Muerdter TE, Sonnenberg M, Aulitzky WE, Schwarz S, Andersson E, Shoshan MC, Havelka AM, Toi M, Linder S.  Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.
Clin Cancer Res. 2007 Jun 1;13(11):3198-206.

Schuler U, Bammer S, Aulitzky WE, Binder C, Böhme A, Egerer G, Sandherr M, Schwerdtfeger R, Silling G, Wandt H, Glasmacher A, Ehninger G.  Safety and efficacy of itraconazole compared to amphotericin B as empirical antifungal therapy for neutropenic fever in patients with haematological
malignancy. Onkologie. 2007 Apr;30(4):185-91. Epub 2007 Mar 23.

Metzgeroth G, Walz C, Score J, Siebert R, Schnittger S, Haferlach C, Popp H, Haferlach T, Erben P, Mix J, Müller MC, Beneke H, Müller L, Del Valle F, Aulitzky WE, Wittkowsky G, Schmitz N, Schulte C, Müller-Hermelink K, Hodges E, Whittaker SJ, Diecker F, Döhner H, Schuld P, Hehlmann R, Hochhaus A, Cross NC, Reiter A.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia. 2007 Jun;21(6):1183-8. Epub 2007 Mar 22.

Heidel F, Cortes J, Rücker FG, Aulitzky W, Letvak L, Kindler T, Huber C, Döhner H, Kantarjian H, Fischer T.  Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib. Cancer. 2007 Mar 1;109(5):907-14.

Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R,  Cerny T, Linch DC.  Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL). Ann Oncol. 2006 Oct;17(10):1546-52. Epub 2006 Aug 3.

Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, Bornhäuser M, Reichle A, Perz J, Haas R, Ganser A, Schmid M, Kanz L, Lenz G, Kaufmann M, Binckebanck A, Brück P, Reutzel R, Gschaidmeier H, Schwartz S, Hoelzer D, Ottmann OG.  Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006 Sep 1;108(5):1469-77. Epub 2006 Apr 25.

van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A,  Simon W, Fritz P, Aulitzky WE.  Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer. 2006 Apr 7;6:86.

Elter T, Borchmann P, Schulz H, Reiser M, Trelle S, Schnell R, Jensen M, Staib P, Schinköthe T, Stützer H, Rech J, Gramatzki M, Aulitzky W, Hasan I, Josting A, Hallek M, Engert A.  Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005 Oct 1;23(28):7024-31. Epub 2005 Sep 6.

Fritz P, Cabrera CM, Dippon J, Gerteis A, Simon W, Aulitzky WE, van der Kuip  H. c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study. Breast Cancer Res. 2005;7(3):R374-84. Epub 2005 Mar 21.

Moehring A, Wohlbold L, Aulitzky WE, van der Kuip H.  Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death. Cell Death Differ. 2005 Jun;12(6):627-36.

van der Kuip H, Wohlbold L, Oetzel C, Schwab M, Aulitzky WE.  Mechanisms of clinical resistance to small molecule tyrosine kinase inhibitors targeting oncogenic tyrosine kinases. Am J Pharmacogenomics. 2005;5(2):101-12. Review.

Lenz G, Dreyling M, Hoster E, Wörmann B, Dührsen U, Metzner B, Eimermacher H,  Neubauer A, Wandt H, Steinhauer H, Martin S, Heidemann E, Aldaoud A, Parwaresch R, Hasford J, Unterhalt M, Hiddemann W.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study  Group (GLSG). J Clin Oncol. 2005 Mar 20;23(9):1984-92. Epub 2005 Jan 24.

Wohlbold L, van der Kuip H, Moehring A, Granot G, Oren M, Vornlocher HP, Aulitzky WE.  All common p210 and p190 Bcr-abl variants can be targeted by RNA interference. Leukemia. 2005 Feb;19(2):290-2.

von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J.  A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor. Blood. 2005 Feb 15;105(4):1652-9. Epub 2004 Sep 30.

Aulitzky WE, Kaufmann M.  Immunotherapy for advanced renal cell carcinoma. Urologe A. 2004 Jan;43(1):85-92; quiz 93. Review. German.

Brugger W, Hirsch J, Grünebach F, Repp R, Brossart P, Vogel W, Kopp HG, Manz MG, Bitzer M, Schlimok G, Kaufmann M, Ganser A, Fehnle K, Gramatzki M, Kanz L.  Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol. 2004 Nov;15(11):1691-8.

van der Kuip H, Moehring A, Wohlbold L, Miething C, Duyster J, Aulitzky WE.  Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines. Leuk Res. 2004 Apr;28(4):405-8.

Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, Neubauer A, Fischer T, Hossfeld DK, Schneller F, Krause SW, Nerl C, Sayer HG,Ottmann OG, Waller C, Aulitzky W, le Coutre P, Freund M, Merx K, Paschka P, König H, Kreil S, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.  Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C. Leukemia. 2003 Dec;17(12):2392-400.

Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE.  Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood. 2003 Sep 15;102(6):2236-9. Epub 2003 May 15.

Pfeifer H, Wassmann B, Hofmann WK, Komor M, Scheuring U, Brück P, Binckebanck  A, Schleyer E, Gökbuget N, Wolff T, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer  D, Ottmann OG.  Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clin Cancer Res. 2003 Oct 15;9(13):4674-81.
 
Wassmann B, Pfeifer H, Scheuring UJ, Binckebanck A, Gökbuget N, Atta J, Brück  P, Rieder H, Schoch C, Leimer L, Schwerdtfeger R, Ehninger G, Lipp T, Perz J, Stelljes M, Gschaidmeier H, Hoelzer D, Ottmann OG.  Early prediction of response in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) treated with imatinib. Blood. 2004 Feb 15;103(4):1495-8. Epub 2003 Oct 23.
 
Wassmann B, Scheuring U, Pfeifer H, Binckebanck A, Käbisch A, Lübbert M, Leimer L, Gschaidmeier H, Hoelzer D, Ottmann OG.  Efficacy and safety of imatinib mesylate (Glivec) in combination with interferon-alpha (IFN-alpha) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Leukemia. 2003 Oct;17(10):1919-24.

Repp R, Schaekel U, Helm G, Thiede C, Soucek S, Pascheberg U, Wandt H, Aulitzky W, Bodenstein H, Sonnen R, Link H, Ehninger G, Gramatzki M; AML-SHG Study Group.  Immunophenotyping is an independent factor for risk stratification in AML. Cytometry B Clin Cytom. 2003 May;53(1):11-9.

Schulz H, Klein SK, Rehwald U, Reiser M, Hinke A, Knauf WU, Aulitzky WE, Hensel M, Herold M, Huhn D, Hallek M, Diehl V, Engert A; German CLL Study Group.  Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002 Nov 1;100(9):3115-20.

Schaich M, Illmer T, Aulitzky W, Bodenstein H, Clemens M, Neubauer A, Repp R, Schäkel U, Soucek S, Wandt H, Ehninger G; SHG AML96 Study Group.  Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged  61-65 years. Haematologica. 2002 Aug;87(8):808-15.

Henkes M, Martin S, Einsele H, Aulitzky WE.  Successful antiviral treatment for fulminant reactivated hepatitis B after autologous stem cell transplantation and prophylaxis during subsequent allogeneic stem cell transplantation. Ann Hematol. 2002 Jun;81(6):343-6. Epub 2002 Jun 4.

Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, Dunst J, Harms D, Reiter A, Henze G, Niemeyer C, Göbel U, Kremens B, Fölsch UR, Aulitzky WE, Voûte PA, Zoubek A, Jürgens H.  Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol. 2001 Nov;12(11):1619-30.

Goetz AW, van der Kuip H, Maya R, Oren M, Aulitzky WE.  Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells. Cancer Res. 2001 Oct 15;61(20):7635-41.

van der Kuip H, Goetz AW, Miething C, Duyster J, Aulitzky WE.  Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis. Blood. 2001 Sep 1;98(5):1532-41.

Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M.  Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn's disease using phenotyping only. Gastroenterology. 2001 Aug;121(2):498-9. No abstract available.

Jonuleit T, van der Kuip H, Miething C, Michels H, Hallek M, Duyster J, Aulitzky WE.  Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and  murine cell lines. Blood. 2000 Sep 1;96(5):1933-9.

Oetzel C, Jonuleit T, Götz A, van der Kuip H, Michels H, Duyster J, Hallek M, Aulitzky WE.  The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X. Clin Cancer Res. 2000 May;6(5):1958-68.

Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE.  Phase I study of subcutaneously administered recombinant human interleukin 12 in  patients with advanced renal cell cancer. Clin Cancer Res. 1999 Dec;5(12):3983-9.

Lindauer M, Domkin D, Döhner H, Kolb HJ, Neubauer A, Huhn D, Kreiter H, Koch  B, Huber C, Aulitzky W, Fischer T.  Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia. Br J Haematol. 1999 Sep;106(4):1013-9.

Fritz P, Seizer-Schmidt R, Mürdter TE, Kroemer HK, Aulitzky W, André S, Gabius HJ, Friedel G, Toomes H, Siegle I.  Ligands for Viscum album agglutinin and galectin-1 in human lung cancer: is there any prognostic relevance? Acta Histochem. 1999 Jul;101(3):239-53.

Busse D, Busch FW, Schweizer E, Bohnenstengel F, Eichelbaum M, Fischer P, Schumacher K, Aulitzky WE, Kroemer HK.  Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism. Cancer Chemother Pharmacol. 1999;43(3):263-8.

Fischer T, Neubauer A, Mohm J, Huhn D, Busemann C, Link H, Arseniev L, Büssing B, Novotny J, Ganser A, Duyster J, Bunjes D, Kreiter S, Aulitzky W, Hehlmann R, Huber C.  Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting  in CML. Bone Marrow Transplant. 1998 May;21(10):1029-36.

Jonuleit T, Peschel C, Schwab R, van der Kuip H, Buchdunger E, Fischer T, Huber C, Aulitzky WE.  Bcr-Abl kinase promotes cell cycle entry of primary myeloid CML cells in the absence of growth factors. Br J Haematol. 1998 Feb;100(2):295-303.

Kolbe K, Domkin D, Derigs HG, Bhakdi S, Huber C, Aulitzky WE.  Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant. 1997 Jan;19(2):143-7.

Wallerath T, Gath I, Aulitzky WE, Pollock JS, Kleinert H, Förstermann U.  Identification of the NO synthase isoforms expressed in human neutrophil granulocytes, megakaryocytes and platelets. Thromb Haemost. 1997 Jan;77(1):163-7.

Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE.  Primary proliferating immature myeloid cells from CML patients are not resistant  to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol. 1996 Dec;95(3):501-7.

Lehrbücher

Aulitzky, W. E., Peschel, C., und Huber, C. Chronische myeloische Leukämie. Kompendium internistischer Onkologie (Hrsg. Schmoll, Höffken, Possinger), 67-92, Springer Verlag 1997.

Aulitzky, W. E., Peschel, C., Schuler M. Hämatologie/Onkologie. Innere Medizin (Hrsg. Lehnert, Schuster), 953-1095, Enke Verlag, 1997

Aulitzky, W. E. und Huber, C. Vitamine und Leukosen. In: Vitamine (Hrsg. Biesalski, Schrezenmeir, Weber, Weiß) Georg Thieme Verlag, 317-320, 1997

Aulitzky W.E., Huber Ch., Nierenzellkarzinom. In: Thiemes Innnere Medizin (Hrsg. M. Freund et al.) Georg Thieme Verlag,  1019-1021, 1999

Aulitzky WE, Beck, J. Huber Ch.  Nierenzellkarzinom In: Die Onkologie (Hrgs Hiddemann, Huber, Bartram) 55.1-19